You are here: Industry Insights > Ryaltris

News List

Glenmark’s Ryaltris nasal spray gets approval in Europe for treatment of allergic rhinitis expresspharma
April 27, 2021
It is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for treatment of symptoms associated with allergic rhinitis (AR) in patients over 12 years of age.
Glenmark, Bausch Health partner to commercialise RYALTRIS nasal spray in Canada expresspharma
March 23, 2021
RYALTRIS is currently under review by Health Canada with a proposed indication for the treatment of seasonal allergic rhinitis in adults and children over 12 years of age.
Glenmark gets marketing approval for Ryaltris, single nasal spray in Russia expresspharma
February 22, 2021
Glenmark Pharmaceuticals announced that its Swiss subsidiary, Glenmark Specialty, received marketing approval from the Ministry of Health of the Russian Federation for its innovative Ryaltris Nasal Spray – a fixed-dose combination nasal spray.
Glenmark Pharma and Menarini enter into exclusive licensing agreement for commercialising Ryaltris for European markets expresspharma
December 23, 2020
Glenmark will receive an upfront payment as well as launch and sales based milestone payments from Menarini for Ryaltris sales.
Glenmark announces approval for Ryaltris in Australia biospectrumasia
December 22, 2019
Glenmark Pharmaceuticals has announced that Seqirus Pty. Ltd. (Seqirus) has received marketing approval for Ryaltris® from the Therapeutic Goods Administration (TGA), Australia. This paves the way for the launch of Ryaltris® in Australia through the partn
FDA Issues Complete Response Letter for Ryaltris americanpharmaceuticalreview
June 26, 2019
India generic drug manufacturer, Glenmark, has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for Ryaltris™ (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg]), Nasal Spray.
Glenmark Pharmaceuticals Announces New Data Presentations on Ryaltris at the ACAAI Annual Scientific Meeting 2018 drugs
November 29, 2018
Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that the company is presenting new data for for its leading respiratory pipeline candidate ....
Glenmark to commercialise Ryaltris in Australia, NZ biospectrumasia
July 09, 2018
Glenmark will receive an upfront payment as well as regulatory and commercial milestone payments from Seqirus.
Glenmark Pharmaceuticals Announces the Company's First NDA for Ryaltris for Patients with Seasonal Allergic Rhinitis drugs
May 31, 2018
Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for its leading respiratory pipeline candidate Ryaltris™ (rye - al' - tris)